Herbal Monograph
Vitex
Vitex agnus-castus L.
Lamiaceae (formerly Verbenaceae)
The premier botanical for female hormonal balance — backed by European pharmacopeia monographs and rigorous clinical trials.
Overview
Plant Description
Aromatic, deciduous shrub or small tree, 1-6 m (occasionally up to 8 m) tall, with a broad, spreading crown. Trunk slender with square young branches; bark gray-brown, smooth becoming fissured with age. Branches flexible, quadrangular, covered with dense gray-white tomentum. Leaves opposite, palmately compound with 5-7 (rarely 3) lanceolate leaflets arranged digitately; leaflets 5-10 cm long, 1-2 cm wide, entire to slightly serrate margins, dark green and glabrous above, gray-white and densely tomentose below with short dense hairs; leaflets aromatic when crushed, with a peppery, sage-like scent. Inflorescence a dense, terminal panicle of verticillasters (whorled clusters), 10-30 cm long, with numerous small, fragrant flowers. Flowers zygomorphic, bilabiate (two-lipped), 6-9 mm long; corolla lilac-blue to violet (rarely white or pink), with the lower lip larger and marked with a darker median streak; calyx campanulate, 5-toothed, densely pubescent. Stamens 4, didynamous, exserted. Fruit a small, round drupe, 3-4 mm in diameter, reddish-black to dark brown at maturity, partially enclosed by the persistent calyx; hard, four-seeded; with a pungent, peppery taste and aromatic odor.
Habitat
Native to the Mediterranean region, Central Asia, and parts of South Asia. Grows naturally along riverbanks, coastal areas, stream margins, and in moist, well-drained soils. Prefers full sun to partial shade. Tolerates a wide range of soil types including sandy, loamy, and clay soils, but requires good drainage. Moderately drought-tolerant once established. Thrives in Mediterranean and warm temperate climates with hot, dry summers and mild, wet winters. Hardy to USDA zones 6-9 (tolerates temperatures down to approximately -15 degrees C).
Distribution
Native range extends across the Mediterranean basin from the Atlantic coast of Morocco and Portugal eastward through southern Europe (Spain, France, Italy, Greece, Turkey), the Black Sea region, the Caucasus, Central Asia (Iran, Afghanistan, Pakistan), and into northwestern India. Widely naturalized in subtropical and warm temperate regions worldwide. Cultivated extensively in southern Europe, particularly in Greece, Italy, and Turkey. Commercial cultivation for pharmaceutical use centered in Mediterranean Europe and Albania. Naturalized and sometimes invasive in parts of the southeastern United States, Australia, and South America.
Parts Used
Ripe dried fruit (berries) (Agni casti fructus; Fructus Agni Casti)
Preferred: Standardized hydroethanolic extract (50-70% ethanol), dried powdered fruit, tincture
The ripe dried fruit is the exclusive part used in modern phytomedicine and is the subject of all major pharmacopeia monographs (European Pharmacopoeia, German Pharmacopoeia), EMA/HMPC assessments, and clinical trials. The fruit contains the full spectrum of bioactive constituents including iridoid glycosides, diterpenes, flavonoids, and essential oil. Both the German Commission E monograph and the EMA/HMPC community herbal monograph are based exclusively on the dried ripe fruit. All major commercially available extracts (BNO 1095, Ze 440, and others) are prepared from the dried ripe fruit.
Leaves and flowering tops
Preferred: Not applicable; leaves are not used in modern practice
Historically used in some traditional preparations but NOT the subject of modern clinical research or pharmacopeia monographs. Leaf essential oil composition differs from fruit oil. Some traditional Mediterranean uses employed leaf infusions. Not recommended for therapeutic use in modern herbal practice; the fruit is the validated medicinal part.
Key Constituents
Iridoid glycosides
Iridoid glycosides are among the primary bioactive constituents of Vitex fruit. Agnuside serves as the key chemical marker for quality control and authentication. While the dopaminergic activity of Vitex is primarily attributed to the diterpene fraction, iridoids contribute to the anti-inflammatory and possibly the neuroendocrine effects. The European Pharmacopoeia requires HPLC identification of agnuside for authenticated Agni casti fructus.
Diterpenes (labdane and clerodane types)
The diterpene fraction is considered the most pharmacologically important constituent group for the hormonal regulatory activity of Vitex agnus-castus. Labdane diterpenes (particularly rotundifuran and vitexilactone) have been shown to bind dopamine D2 receptors in vitro, providing a plausible molecular mechanism for the prolactin-lowering effect documented in clinical studies. Wuttke et al. 2003 demonstrated that the lipophilic extract fraction containing diterpenes showed the strongest dopaminergic activity in pituitary cell assays. This dopamine agonist activity at the pituitary is the principal pharmacological explanation for Vitex's effects on the hypothalamic-pituitary-gonadal (HPG) axis.
Flavonoids
Flavonoids contribute to the anti-inflammatory and possibly mild estrogenic activity of Vitex preparations. Casticin is the most pharmacologically studied flavonoid from Vitex and serves as the quality control marker in the European Pharmacopoeia (minimum 0.08% in dried fruit). The polymethoxylated flavones in Vitex may have mild affinity for estrogen receptors (particularly ERbeta), which could contribute to the overall hormonal modulatory effect, though this is considered secondary to the dopaminergic mechanism.
Essential oil (volatile oil)
Essential oil comprises approximately 0.5-1.8% of the dried fruit. Over 50 components have been identified, with substantial variation by chemotype and geographic origin. Mediterranean chemotypes tend to be higher in sabinene and 1,8-cineole. The volatile oil contributes to the carminative and mild spasmolytic activity of the whole fruit but is NOT considered the primary source of the hormonal regulatory effects (those are attributed to the diterpene and potentially flavonoid fractions). Essential oil composition is useful for chemotaxonomic characterization and quality control.
Other constituents
Minor constituents contributing to the overall phytochemical matrix. The fatty acid fraction may contribute to extract bioactivity but is not considered a primary active component. The historical claim that Vitex contains meaningful amounts of phytoprogestins is not well-supported; the dopaminergic mechanism is now the accepted primary mode of action.
Herbal Actions
Stimulates or increases menstrual flow
Vitex is one of the most well-established emmenagogues in Western herbal medicine, acting to regulate and normalize the menstrual cycle. Its mechanism is indirect: by reducing elevated prolactin levels through dopamine D2 receptor agonism at the pituitary, Vitex normalizes the pulsatile release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). This cascade effect supports normal corpus luteum function, adequate progesterone production in the luteal phase, and regular menstrual cyclicity. Clinical trials demonstrate normalization of shortened or irregular cycles, restoration of ovulation in amenorrheic or oligomenorrheic women, and correction of luteal phase deficiency. Commission E approved Vitex for menstrual irregularities.
[1, 2, 11]Relieves smooth muscle spasm
Demonstrates smooth muscle relaxant activity, particularly relevant to the uterine musculature. Contributes to relief of menstrual cramping and pelvic pain associated with PMS and dysmenorrhea. The antispasmodic action complements the hormonal regulatory effects.
[15]Reduces inflammation
In vitro and animal studies demonstrate anti-inflammatory activity attributable to iridoid glycosides (agnuside, aucubin) and flavonoids (casticin). Casticin inhibits NF-kB activation and COX-2 expression in cell culture models. Clinically relevant for cyclical mastalgia and premenstrual inflammatory symptoms. The anti-inflammatory action supports but does not replace the primary dopaminergic mechanism.
[2]Reduces anxiety
Vitex demonstrates anxiolytic effects, likely mediated through multiple mechanisms: modulation of GABAergic activity, mu-opioid receptor binding (by vitexilactone and other diterpenes), and indirect hormonal stabilization. Clinical trials note significant improvement in anxiety/irritability subscale scores in PMS symptom assessments. The anxiolytic effect is most evident in the context of premenstrual and perimenopausal mood disturbances rather than as a standalone anxiolytic.
[6, 13]Promotes breast milk production
Paradoxically, despite its prolactin-lowering effects at higher doses, Vitex has a historical reputation as a galactagogue (milk promoter). This may be explained by a biphasic dose-response: lower doses may stimulate prolactin release (possibly via blockade of dopamine D2 receptors at low concentrations or other receptor interactions), while higher doses inhibit prolactin via dopamine D2 agonism. The galactagogue use is traditional and not supported by modern clinical trials. Current evidence favors Vitex's role as a prolactin-lowering agent. This traditional use should be approached with caution.
[15]Modulates and balances immune function
In vitro studies suggest immunomodulatory activity, including modulation of T-cell proliferation and cytokine production. Casticin and other flavonoids may modulate immune function. Clinical relevance in the context of reproductive health is speculative but may contribute to the overall therapeutic effect in conditions with immune dysregulation components.
[2]Therapeutic Indications
Reproductive System
Premenstrual syndrome (PMS)
The most extensively studied indication for Vitex agnus-castus. Schellenberg 2001 landmark RCT (n=170): Vitex extract Ze 440 (20 mg/day) was significantly superior to placebo for a self-assessment PMS symptom score (52% reduction vs 24% placebo, P<0.001), with marked improvement in irritability, mood alteration, anger, headache, breast fullness, and bloating. Ma et al. 2010 meta-analysis of 8 RCTs confirmed significant efficacy for PMS with a pooled relative risk of symptom improvement of 2.57 (95% CI 1.24-5.33). Verkaik et al. 2017 systematic review corroborated these findings. BNO 1095 (Bionorica) extract showed similar efficacy in multiple studies. Commission E, EMA/HMPC (well-established use), and WHO support this indication. Typical treatment duration: at least 3 menstrual cycles. The EMA HMPC has granted Vitex fruit 'well-established use' status for PMS, the highest evidence category for herbal medicines.
[1, 2, 6, 7]Menstrual cycle irregularities (oligomenorrhea, polymenorrhea, secondary amenorrhea)
Commission E approved indication. Multiple clinical studies demonstrate normalization of menstrual cycle length and regularity. Milewicz et al. 1993 study (n=52): Vitex extract significantly reduced prolactin levels, normalized shortened luteal phase, and corrected progesterone deficiency in women with latent hyperprolactinemia. Gerhard et al. 1998 study showed restoration of menstrual regularity and ovulation in amenorrheic women. The mechanism involves normalization of the HPG axis through prolactin reduction, restoring normal GnRH pulsatility and downstream LH/FSH balance. This corrects the underlying endocrine dysfunction rather than merely masking symptoms.
[1, 2, 8]Luteal phase deficiency (corpus luteum insufficiency)
Luteal phase deficiency -- characterized by a shortened luteal phase (less than 10 days), low mid-luteal progesterone, and inadequate endometrial maturation -- is a recognized cause of infertility and early pregnancy loss. Vitex addresses luteal phase deficiency by reducing elevated prolactin (which suppresses progesterone production) and normalizing LH pulsatility. Milewicz et al. 1993 demonstrated that Vitex normalized luteal phase length and increased mid-luteal progesterone levels. Westphal et al. 2004 (FertilityBlend study) showed improved progesterone levels and pregnancy rates in women with luteal phase deficiency, though FertilityBlend contained multiple ingredients. The EMA assessment acknowledges traditional use for this indication.
[2, 8, 10]Cyclical mastalgia (premenstrual breast pain/tenderness)
Cyclical mastalgia is one of the most responsive symptoms to Vitex therapy. The mechanism is directly linked to prolactin reduction: elevated prolactin stimulates breast tissue proliferation and fluid retention. Halaska et al. 1999 RCT (n=97): Vitex extract (mastodynon) was significantly superior to placebo for cyclical mastalgia, with a 52.2% responder rate vs 23.7% (P=0.006). Wuttke et al. 2003 confirmed the prolactin-lowering mechanism underlying this effect. Breast pain/fullness consistently improves in PMS trials as a subscale outcome.
[6, 9, 11]Female infertility (luteal phase-related)
By normalizing luteal phase function and correcting mild hyperprolactinemia, Vitex can improve fertility in women whose infertility is attributable to hormonal imbalance. Gerhard et al. 1998: women receiving Vitex for 3 months showed higher pregnancy rates than placebo (21% vs 10%). Westphal et al. 2004 (FertilityBlend containing Vitex): pregnancy rate of 26% vs 10% placebo over 3 months in women with infertility. IMPORTANT: Vitex is appropriate for infertility related to luteal insufficiency, mild hyperprolactinemia, or ovulatory dysfunction -- not for structural causes (tubal obstruction, endometriosis), severe ovulatory failure, or male-factor infertility.
[2, 10]Hyperprolactinemia (mild, functional)
Vitex reduces mildly elevated prolactin through its dopaminergic mechanism (D2 receptor agonism at the pituitary lactotroph cells). Milewicz et al. 1993 demonstrated significant prolactin reduction in women with latent hyperprolactinemia (mildly elevated baseline levels). IMPORTANT: Vitex is appropriate for mild functional (idiopathic or stress-related) hyperprolactinemia. It is NOT appropriate for prolactinoma or other pathological causes of hyperprolactinemia, which require medical evaluation and may need dopamine agonist drugs (cabergoline, bromocriptine). Always rule out pituitary tumor before attributing hyperprolactinemia to a functional cause.
[8, 11]Endocrine System
Menopausal symptoms
Some evidence suggests Vitex may ameliorate vasomotor symptoms (hot flashes) and mood disturbances during perimenopause and early menopause. The mechanism may involve modulation of the HPG axis during the transition period. van Die et al. 2009 reviewed evidence for Vitex in menopause and found some supportive data, though the evidence base is smaller than for PMS. Vitex is not a first-line botanical for established menopause (black cohosh, red clover, and soy isoflavones have stronger evidence for menopausal vasomotor symptoms), but may be useful during perimenopause when menstrual irregularity coexists with emerging menopausal symptoms.
[2, 14]Acne (hormonally-driven, premenstrual flares)
Limited evidence supports Vitex for hormonally-driven acne, particularly premenstrual acne flares. The mechanism relates to normalization of the estrogen-to-progesterone ratio and possible effects on androgens. Some PMS trials report improvement in skin symptoms as a secondary outcome. Dedicated acne-specific trials are lacking. Vitex is sometimes included in naturopathic protocols for hormonal acne in combination with other therapies.
[2]Nervous System
Premenstrual anxiety and irritability
Anxiety, irritability, and mood swings are among the most commonly reported PMS symptoms and among the most responsive to Vitex treatment. In the Schellenberg 2001 RCT, irritability and mood alteration showed significant improvement with Vitex. He et al. 2009 study also demonstrated anxiolytic effects. The mechanism may involve GABAergic modulation, mu-opioid receptor activity, and indirect effects of hormonal stabilization on neurotransmitter function. Vitex is not indicated as a general-purpose anxiolytic but specifically addresses cyclical mood disturbances tied to the menstrual cycle.
[6, 13]Premenstrual insomnia and sleep disturbance
Traditional use for premenstrual sleep disturbances. May be secondary to anxiolytic and hormonal stabilizing effects. Not specifically studied in dedicated sleep trials. Often combined with other calming herbs (valerian, passionflower) in formulations for premenstrual sleep difficulties.
[15]Energetics
Temperature
slightly warm
Moisture
dry
Taste
Tissue States
damp/stagnation, cold/depression
Vitex is considered slightly warm and dry in Western energetic terms. Its pungent and bitter taste profiles reflect its aromatic volatile oils and iridoid glycosides, respectively. The slight warmth and drying quality align with its traditional use for conditions associated with stagnation and dampness in the reproductive system (irregular or delayed menses, excessive or congestive premenstrual symptoms). In the Physiomedicalist tradition, Vitex would be considered a diffusive stimulant to the reproductive organs, promoting healthy flow and resolving pelvic congestion. The aromatic quality indicates volatile-oil-driven dispersive action. In traditional Greek and Mediterranean use, the berries were considered drying and warming to the reproductive system, hence their use for regulating menstrual function. The paradoxical name 'chaste tree' reflects the medieval belief that it could suppress libido (an anaphrodisiac effect), which may relate to its prolactin-modulating activity -- hyperprolactinemia can indeed reduce libido.
Traditional Uses
Ancient Greek Medicine
- Hippocrates (c. 460-370 BCE): Recommended the berries for injuries and inflammation, and for facilitating the expulsion of the afterbirth
- Dioscorides (De Materia Medica, c. 70 CE): Described agnus castus as an emmenagogue and galactagogue; recommended the fruit for promoting menstruation and milk flow; also noted it as an anaphrodisiac (suppresses sexual desire)
- Pliny the Elder (Naturalis Historia, c. 77 CE): Described the plant's use at the Thesmophoria festival, where Athenian women strewed their beds with the leaves to maintain chastity during the rites
- Theophrastus (Historia Plantarum, c. 300 BCE): Described the plant's morphology and noted its traditional associations with chastity and reproductive health
"Vitex agnus-castus has one of the longest documented histories of use in Western herbal medicine. The name itself encodes the traditional association with chastity: 'agnus' is a Latinized form of the Greek 'agnos' (meaning pure/chaste), and 'castus' is Latin for chaste. The Greek name 'lygos' was also used. The plant was sacred to Hera (Juno in Roman tradition), goddess of marriage and childbirth. Dioscorides' recommendation as both an emmenagogue and anaphrodisiac established a dual reputation that persisted through the medieval period."
[15]
Medieval European / Monastic Medicine
- Consumed by monks in European monasteries to suppress libido and maintain their vows of chastity -- hence the common name 'Monk's Pepper'
- Berries added to food as a spice and anaphrodisiac in monastic kitchens
- Used by nuns and monks alike as an aid to celibacy
- Continued use as an emmenagogue and for menstrual complaints in medieval herbals
- Hildegard von Bingen (12th century) referenced the plant in her botanical writings
"The widespread monastic use of Vitex berries as an anaphrodisiac (known as 'Monk's Pepper' or 'Agnus Castus') is one of the best-documented examples of institutional herbal use in medieval Europe. The pungent, peppery berries were ground and added to food. Whether the anaphrodisiac effect was genuine or the result of expectation and ritual context is debated. Modern pharmacology offers a partial explanation: Vitex's prolactin-lowering effect could theoretically reduce libido (hyperprolactinemia is associated with decreased libido, but normalizing prolactin should not reduce libido below normal levels)."
[15]
Eclectic Medicine (19th-20th century American)
- Used for menstrual irregularities, amenorrhea, and dysmenorrhea
- Recommended for insufficient lactation (galactagogue use)
- Used for symptoms associated with the 'change of life' (menopause)
- Employed for sexual atony and reproductive weakness
- Combined with other reproductive tonics such as Caulophyllum (blue cohosh) and Helonias (false unicorn root)
"King's American Dispensatory (Felter and Lloyd, 1898) describes Agnus Castus for 'sexual atony,' menstrual irregularities, and as a galactagogue. The Eclectic physicians valued it primarily as a uterine tonic and menstrual regulator. Fyfe's Pocket Essentials of Modern Materia Medica and Therapeutics (1903) lists it for 'sexual melancholy' and menstrual suppression. The Eclectic tradition preserved and transmitted the reproductive uses from earlier European herbal practice."
[15]
Modern European Phytotherapy (20th-21st century)
- First-line botanical treatment for premenstrual syndrome (PMS)
- Menstrual cycle regulation (oligomenorrhea, polymenorrhea, secondary amenorrhea)
- Cyclical mastalgia (premenstrual breast pain)
- Luteal phase deficiency and related infertility
- Mild hyperprolactinemia (functional, non-pathological)
- Perimenopausal menstrual irregularities
"Vitex agnus-castus is one of the most extensively researched and widely prescribed herbal medicines in modern European phytotherapy, particularly in Germany where it has been subject to rigorous pharmacological and clinical investigation since the 1950s. The German pharmaceutical company Bionorica developed the BNO 1095 extract, while Zeller AG developed Ze 440 -- both are clinically validated standardized extracts. Vitex preparations are among the most commonly prescribed herbal medicines by gynecologists in Germany. The EMA/HMPC granted 'well-established use' status for PMS in 2018, the highest evidence category, and 'traditional use' status for menstrual irregularities."
Modern Research
Landmark RCT for PMS: Vitex agnus-castus extract Ze 440
Prospective, randomized, double-blind, placebo-controlled trial of 170 women with PMS (DSM-III-R criteria) over 3 consecutive menstrual cycles. Women received 20 mg of the standardized Vitex extract Ze 440 or placebo daily.
Findings: The Vitex group showed significantly greater improvement in the PMS symptom self-assessment score compared to placebo (52% vs 24% reduction, P<0.001). All six PMS symptom subscales improved significantly: irritability, mood alteration, anger, headache, breast fullness, and other symptoms including bloating. Physician global assessment also favored Vitex (CGI responder rate 52% vs 24%). Adverse events were mild and comparable between groups (mild gastrointestinal complaints and skin reactions).
Limitations: Single-center study. DSM-III-R criteria rather than newer ISPMD or ACOG diagnostic criteria. 3 months treatment duration -- longer-term data from this trial not available. Self-assessment as primary endpoint is subjective. Ze 440 is a specific standardized extract, and results may not be generalizable to other Vitex preparations.
[6]
Meta-analysis of Vitex for premenstrual syndrome
Systematic review and meta-analysis of 8 randomized controlled trials evaluating Vitex agnus-castus preparations for PMS symptoms.
Findings: Pooled analysis showed Vitex was significantly superior to placebo for overall PMS symptom improvement (RR 2.57, 95% CI 1.24-5.33). Vitex was at least as effective as vitamin B6 (pyridoxine) and magnesium oxide in head-to-head comparisons. Physical symptoms (breast tenderness, bloating, headache) and psychological symptoms (irritability, mood disturbance) both improved significantly. Treatment duration across trials ranged from 2 to 6 menstrual cycles.
Limitations: Significant heterogeneity in preparations (different extracts, doses), diagnostic criteria for PMS, and outcome measures. Some trials had small sample sizes. Publication bias cannot be excluded. Different Vitex extracts may have different constituent profiles and potencies.
[7]
Dopaminergic mechanism: in vitro and in vivo evidence
Series of studies investigating the molecular mechanism of Vitex's prolactin-lowering effect using pituitary cell cultures, receptor binding assays, and clinical pharmacology.
Findings: The lipophilic fraction of Vitex extract (containing diterpenes including rotundifuran and vitexilactone) binds to dopamine D2 receptors and inhibits prolactin secretion from cultured rat pituitary cells in a dose-dependent manner. The effect is blocked by the D2 antagonist haloperidol, confirming a dopaminergic mechanism. In vivo, Vitex extract reduced elevated serum prolactin in both animal models and human subjects (Milewicz et al. 1993). The dopaminergic activity is concentrated in the lipophilic fraction rather than the hydrophilic (aqueous) fraction, pointing to diterpenes as the responsible compounds. This mechanism explains the downstream effects on GnRH pulsatility, LH/FSH balance, and progesterone production.
Limitations: Most mechanistic work is in vitro or in animal models. Bioavailability of individual diterpenes after oral administration needs further characterization. The relative contribution of dopaminergic vs other mechanisms (opioidergic, GABAergic) in vivo is not fully delineated.
RCT for cyclical mastalgia: Vitex vs placebo
Randomized, double-blind, placebo-controlled trial of 97 women with cyclical mastalgia treated with Vitex agnus-castus extract (mastodynon) or placebo over 3 menstrual cycles.
Findings: Vitex was significantly superior to placebo for reduction of cyclical breast pain. Responder rate (defined as more than 50% reduction in pain intensity on VAS) was 52.2% in the Vitex group vs 23.7% in the placebo group (P=0.006). Mean pain intensity reduction was significantly greater with Vitex. Prolactin levels decreased in the Vitex group, consistent with the dopaminergic mechanism. Adverse events were mild and infrequent.
Limitations: Moderate sample size. 3-cycle treatment duration. Mastodynon is a combination product that includes Vitex as the principal ingredient but is not a monopreparation. Placebo response rate of 23.7% indicates a meaningful placebo effect for this subjective symptom.
[9]
Vitex for luteal phase deficiency and hyperprolactinemia
Clinical study of 52 women with luteal phase defects due to latent hyperprolactinemia, treated with Vitex agnus-castus extract (20 mg daily) or placebo for 3 months.
Findings: Vitex significantly reduced prolactin release (as measured by TRH-stimulated prolactin levels), normalized shortened luteal phase duration, corrected luteal phase progesterone deficits, and reduced premenstrual symptoms including breast tenderness. The prolactin-lowering effect was sustained over the 3-month treatment period. No significant adverse effects were reported.
Limitations: Relatively small sample size (n=52). Focused on the specific subpopulation with latent hyperprolactinemia rather than the general PMS population. Older study (1993) with methodology that does not fully meet current reporting standards.
[8]
EMA/HMPC Assessment: well-established and traditional use evaluation
Comprehensive assessment by the European Medicines Agency Committee on Herbal Medicinal Products (HMPC) evaluating the clinical evidence, pharmacology, and safety of Vitex agnus-castus fruit preparations.
Findings: The HMPC concluded that there is sufficient clinical evidence for 'well-established use' of Vitex agnus-castus dry extract (corresponding to 8-13 mg native dry extract, extraction solvent ethanol 60% V/V, DER 7-13:1) for the relief of premenstrual complaints including irritability, mood alteration, breast tenderness, headache, and bloating. A separate 'traditional use' registration was granted for menstrual irregularities. The assessment confirmed the dopaminergic mechanism and acceptable safety profile. Treatment duration recommended: at least 3 months. Effects may not be noticeable until after the first menstrual cycle of treatment.
Limitations: The assessment is specific to the extract specification described (not all commercial products meet this specification). The well-established use status is limited to PMS; other indications (infertility, mastalgia) are addressed under traditional use or require further clinical evidence.
[2]
FertilityBlend study: Vitex-containing supplement for female infertility
Double-blind, placebo-controlled trial of 93 women with infertility (trying to conceive for 6-36 months). Participants received FertilityBlend (containing Vitex agnus-castus, green tea, L-arginine, vitamins, and minerals) or placebo for 3 months.
Findings: After 3 months, 26% of women in the FertilityBlend group became pregnant versus 10% in the placebo group (P=0.01). Progesterone levels, luteal phase length, and basal body temperature patterns improved significantly in the treatment group. Number of days with late-cycle elevated basal temperature increased, suggesting improved corpus luteum function.
Limitations: FertilityBlend is a multi-ingredient supplement; the effects cannot be attributed solely to Vitex. Relatively small sample size. 3-month duration is short for an infertility intervention. The study population was heterogeneous in terms of infertility etiology.
[10]
Preparations & Dosage
Standardized Extract
Strength: DER (Drug-Extract Ratio) typically 6-12:1 or 7-13:1, extraction solvent ethanol 50-70% V/V. Standardized to casticin (minimum 0.6-1.0 mg per dose) and/or agnuside.
Commercially prepared standardized hydroethanolic extracts of Vitex agnus-castus dried fruit. Major validated extracts include Ze 440 (Zeller AG, standardized to casticin content) and BNO 1095 (Bionorica, standardized for overall diterpene and flavonoid profile). These are the forms used in the major clinical trials.
Extract-specific: Ze 440: 20 mg once daily. BNO 1095: 4 mg once daily (this is a concentrated extract; the DER is approximately 6-12:1). For general Vitex dry extract (60% ethanol, DER 7-13:1): 8-13 mg daily as per EMA/HMPC monograph. Taken as a single morning dose.
Once daily, preferably in the morning
Minimum 3 menstrual cycles (approximately 3 months). Effects may not be evident until after the first cycle. May be continued for up to 6 months or longer under practitioner supervision. Reassess after 6 months.
Not recommended for children or adolescents under 18 years. Not studied in pediatric populations.
Standardized extracts are the preferred form for clinical use, as they provide consistent dosing of active constituents and are the forms validated in clinical trials. The daily dose of native dry extract ranges from 4 mg (BNO 1095, a highly concentrated extract) to 20 mg (Ze 440). These seemingly different doses reflect different drug-extract ratios and concentration factors. The EMA HMPC monograph specifies the extract parameters precisely for well-established use.
Tincture
Strength: 1:5, 60-70% ethanol
Macerate dried ripe Vitex fruit (crushed or coarsely ground) in 60-70% ethanol at a ratio of 1:5 for 2-4 weeks with regular agitation. Press and filter.
1-2 mL (approximately 20-40 drops), taken once daily in the morning with a small amount of water
Once daily, morning dosing preferred
Minimum 3 months. Reassess after 6 months.
Not recommended for children or adolescents under 18
Tincture is a traditional preparation method widely used by Western herbalists. The higher alcohol percentage (60-70%) is necessary to extract both the lipophilic diterpenes and flavonoids and the hydrophilic iridoid glycosides. Morning dosing is recommended because prolactin release follows a circadian rhythm with peak levels during sleep; morning dosing aligns with the natural hormonal rhythm. Some practitioners use a 1:3 tincture strength for more concentrated dosing.
[15]
capsule-powder
Strength: 500-1000 mg powdered dried fruit per capsule
Fill capsules with finely powdered dried ripe Vitex fruit. Grind dried berries immediately before encapsulation to preserve volatile oil content.
500-1000 mg dried fruit powder, taken once daily in the morning. Some traditional dosing protocols use up to 1800 mg/day.
Once daily, morning
Minimum 3 months. Reassess after 6 months.
Not recommended for children or adolescents under 18
Crude powdered fruit capsules are widely available commercially but are less well-studied than standardized extracts. The constituent profile of crude powder differs from standardized extracts, and dose equivalence is not established. Standardized extracts are preferred when available. The crude fruit does, however, contain the full spectrum of constituents and has traditional and Eclectic precedent.
[15]
Infusion (Tea)
Strength: 2-4 g dried crushed fruit per 240 mL water
Lightly crush 1-2 teaspoons (approximately 2-4 g) of dried Vitex berries. Pour 240 mL (8 oz) of just-boiled water over the crushed berries. Cover and steep for 15-20 minutes. Strain.
1 cup (240 mL) once daily, morning
Once daily
Minimum 3 months
Not recommended
Infusion is the simplest traditional preparation method but may extract fewer of the lipophilic diterpenes (which are the primary dopaminergic compounds) compared to ethanolic preparations. Hot water will extract iridoid glycosides and some flavonoids effectively. For maximum therapeutic effect in hormonal indications, tincture or standardized extract is preferred over aqueous infusion. Tea may be useful as a supportive preparation or for milder symptoms.
[15]
fluid-extract
Strength: 1:1 or 1:2 fluid extract in 60-70% ethanol
Concentrated liquid extract of Vitex agnus-castus fruit prepared by percolation or maceration followed by concentration. Typically 1:1 or 1:2 in 60-70% ethanol.
0.5-1 mL once daily in the morning
Once daily, morning
Minimum 3 months
Not recommended
More concentrated than a standard tincture. Used by professional herbalists for precise dosing. The higher concentration means a smaller volume delivers the same amount of plant material. Ensure the alcohol percentage is adequate for extraction of lipophilic diterpenes.
[15]
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Due to Vitex's modulation of the HPG axis and potential mild estrogenic activity of some flavonoid constituents, use is contraindicated or should be avoided in hormone-sensitive conditions. While Vitex is not directly estrogenic in the way phytoestrogens (soy isoflavones) are, its effects on the estrogen-progesterone balance theoretically could influence hormone-sensitive tissue proliferation. The EMA assessment notes this precaution. Women with a history of hormone-sensitive cancers should avoid Vitex.
Vitex's modulation of the HPG axis (prolactin reduction, GnRH/LH/FSH effects) can theoretically interfere with hormonal contraception and HRT. Concurrent use may reduce the efficacy of oral contraceptives or create unpredictable hormonal interactions. Women using hormonal contraceptives, undergoing HRT, or in IVF/ART protocols should not use Vitex unless specifically directed by their treating physician.
Vitex acts as a dopamine D2 receptor agonist. Concurrent use with pharmaceutical dopamine agonists (bromocriptine, cabergoline, pramipexole) could theoretically produce additive dopaminergic effects. Concurrent use with dopamine antagonists (antipsychotics such as haloperidol, risperidone; antiemetics such as metoclopramide, domperidone) could result in pharmacological antagonism, reducing the efficacy of either the drug or Vitex. This interaction is mechanistically sound based on shared receptor targets.
Vitex is contraindicated during pregnancy. Its effects on the HPG axis, prolactin, and potentially uterine smooth muscle make it inappropriate during gestation. While no teratogenic effects have been documented, the hormonal modulatory mechanism presents an unacceptable theoretical risk. Vitex should be discontinued once pregnancy is confirmed (even if it was used to support conception). This is consistent with Commission E, EMA, and WHO guidance.
Rare but documented. Allergic reactions including skin rash, urticaria, and pruritus have been reported. Cross-reactivity with other Lamiaceae members is theoretically possible but not well-documented.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Dopamine agonists (bromocriptine, cabergoline, pramipexole, ropinirole) (Dopamine agonists) | moderate | Pharmacodynamic: additive dopaminergic effect. Vitex acts as a D2 receptor agonist; combining with pharmaceutical dopamine agonists could potentiate dopaminergic activity, potentially increasing the risk of adverse effects such as nausea, dizziness, and hypotension. |
| Dopamine antagonists / antipsychotics (haloperidol, risperidone, olanzapine, chlorpromazine) and antiemetics (metoclopramide, domperidone) (Dopamine antagonists) | moderate | Pharmacodynamic: antagonism at D2 receptors. Vitex's D2 agonist activity could theoretically reduce the efficacy of dopamine-blocking drugs (antipsychotics, antiemetics). Conversely, these drugs could block Vitex's therapeutic mechanism. |
| Oral contraceptives and hormone replacement therapy (Hormonal medications) | moderate | Pharmacodynamic: Vitex modulates the HPG axis, affecting GnRH, LH, FSH, and prolactin. This could interfere with the hormonal feedback loops that oral contraceptives rely on for efficacy. Theoretical reduction in contraceptive reliability. |
| In vitro fertilization (IVF) medications (gonadotropins, GnRH agonists/antagonists) (Fertility drugs) | moderate | Vitex modulates the HPG axis at multiple levels. Concurrent use during controlled ovarian hyperstimulation could interfere with the precise hormonal control required for IVF protocols. |
Pregnancy & Lactation
Pregnancy
contraindicated
Lactation
caution
Pregnancy: Vitex is contraindicated during pregnancy. Although used historically to promote conception, it should be discontinued immediately upon confirmed pregnancy. The hormonal modulatory effects (HPG axis modulation, prolactin reduction) pose theoretical risks during gestation. No teratogenic effects have been documented in animal studies or human use, but the hormonal mechanism makes use during pregnancy inappropriate. Commission E, EMA, and most authoritative references advise against use during pregnancy. Lactation: The use during breastfeeding is controversial. Traditional galactagogue reputation exists, but the well-documented prolactin-lowering mechanism at therapeutic doses raises concern that Vitex could reduce milk supply. Some sources suggest that very low doses might paradoxically increase prolactin (biphasic dose-response theory), but this is speculative. The EMA advises against use during lactation due to insufficient safety data. Avoid during breastfeeding unless under professional supervision with specific clinical rationale.
Adverse Effects
References
Monograph Sources
- [1] German Commission E (Bundesinstitut fur Arzneimittel und Medizinprodukte). Commission E Monograph: Agni casti fructus (Chaste Tree Fruit) -- Positive. Bundesanzeiger (Federal Gazette) (1998)
- [2] Committee on Herbal Medicinal Products (HMPC), European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. European Medicines Agency (2018)
- [3] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Fructus Agni Casti. World Health Organization, Geneva (2009) : 8-29
- [4] European Scientific Cooperative on Phytotherapy (ESCOP). ESCOP Monographs: Agni casti fructus -- Agnus Castus Fruit. ESCOP Monographs, 2nd edition. Thieme, Stuttgart (2003)
- [5] National Center for Complementary and Integrative Health (NCCIH). Chasteberry. NCCIH, National Institutes of Health (2020)
Clinical Studies
- [6] Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ (2001) ; 322 : 134-137 . DOI: 10.1136/bmj.322.7279.134 . PMID: 11159568
- [7] Ma L, Lin S, Chen R, Zhang Y, Chen F, Wang X. Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust N Z J Obstet Gynaecol (2010) ; 50 : 189-193 . DOI: 10.1111/j.1479-828X.2010.01137.x . PMID: 20522079
- [8] Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, Schmitz H. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinaemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung (1993) ; 43 : 752-756 . PMID: 8369008
- [9] Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast (1999) ; 8 : 175-181 . DOI: 10.1054/brst.1999.0039 . PMID: 14731436
- [10] Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp Obstet Gynecol (2004) ; 31 : 296-300 . PMID: 15672972
- [11] Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus) -- pharmacology and clinical indications. Phytomedicine (2003) ; 10 : 348-357 . DOI: 10.1078/094471103322004866 . PMID: 12809367
- [12] Jarry H, Spengler B, Porzel A, Schmidt J, Wuttke W, Christoffel V. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med (2003) ; 69 : 945-947 . DOI: 10.1055/s-2003-45105 . PMID: 14648399
- [13] He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S, Yao Y, Lu J, Lin S. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas (2009) ; 63 : 99-103 . DOI: 10.1016/j.maturitas.2009.01.006 . PMID: 19269753
- [14] van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of health conditions affecting women's reproductive health. Planta Med (2009) ; 75 : 1-18
Traditional Texts
- [15] Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone/Elsevier (2013)
- [16] Felter HW, Lloyd JU. King's American Dispensatory (18th edition, 3rd revision). Ohio Valley Company, Cincinnati (1898)
- [17] Mills S, Bone K. The Essential Guide to Herbal Safety. Churchill Livingstone/Elsevier (2005)
Pharmacopeias & Reviews
- [18] European Pharmacopoeia Commission. European Pharmacopoeia Monograph: Agnus castus fruit (Agni casti fructus). European Pharmacopoeia (Ph. Eur.), Council of Europe, Strasbourg (2020)
- [19] van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med (2013) ; 79 : 562-575 . DOI: 10.1055/s-0032-1327831 . PMID: 23136064
Last updated: 2026-02-26 | Status: review